Description: Botanix Pharmaceuticals Limited, a clinical stage cannabinoid therapeutics company, develops therapeutics for serious skin diseases in Australia. It offers BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1308, a transdermal gel formulation for the treatment of plaque psoriasis; BTX 1204, a transdermal gel formation for the treatment of atopic dermatitis; BTX 1701, a novel product for mild acne; and BTX 1801, a novel antimicrobial. The company is based in North Perth, Australia.
Home Page: www.botanixpharma.com
41 – 47 Colin Street
West Perth,
WA
6005
Australia
Phone:
61 8 6555 2945
Officers
| Name | Title |
|---|---|
| Mr. Vincent P. Ippolito | MD & Executive Chairman |
| Dr. Howie McKibbon | Chief Executive Officer |
| Mr. Graeme Morissey | Chief Financial Officer |
| Mr. Matthew Callahan L.L.B., M.B.A., MBA LLB | Executive Director |
| Dr. Jack Hoblitzell Ph.D. | Senior Vice President of Pharmaceutical Development |
| Dr. Patricia S. Walker M.D., Ph.D. | Chief Medical Adviser |
| Dr. Boris Meyerson Ph.D. | Chief Business Officer |
| Mr. David Morgan | Head of Corporate Affairs |
| Mr. Kevin Wojciechowski | Head of HCP Marketing & Sales Training |
| Ms. Susan Patricia Park A.C.A., A.C.I.S., ACSA, AGIA, B.Com., C.A., F Fin | Company Secretary |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.8715 |
| Price-to-Sales TTM: | 263.49 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |